Timothy L Vollmer1, Kavita V Nair1, Ian M Williams1, Enrique Alvarez1. 1. Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
Abstract
PURPOSE OF REVIEW: This review presents the hypothesis that loss of neurologic reserve explains onset of progressive multiple sclerosis (PrMS). RECENT FINDINGS: Evidence supporting the separate classification of PrMS and relapsing multiple sclerosis (RMS) is limited and does not explain PrMS or the response of these patients to therapy. SUMMARY: We argue that multiple sclerosis (MS) progresses along a continuum from RMS to PrMS, with differing levels of neurologic reserve accounting for phenotypic differences. In early MS, inflammation causes brain atrophy with symptoms buffered by neurologic reserve. As brain loss from normal aging and MS continues, reserve is depleted and effects of subclinical MS disease activity and aging are unmasked, manifesting as PrMS. Most therapies show limited benefit in PrMS; patients are older, have fewer inflammatory events, and the effects of aging cause continued loss of neurologic function, even if inflammation is terminated. Loss of neurologic reserve means patients with PrMS cannot recover function, unlike patients with RMS.
PURPOSE OF REVIEW: This review presents the hypothesis that loss of neurologic reserve explains onset of progressive multiple sclerosis (PrMS). RECENT FINDINGS: Evidence supporting the separate classification of PrMS and relapsing multiple sclerosis (RMS) is limited and does not explain PrMS or the response of these patients to therapy. SUMMARY: We argue that multiple sclerosis (MS) progresses along a continuum from RMS to PrMS, with differing levels of neurologic reserve accounting for phenotypic differences. In early MS, inflammation causes brain atrophy with symptoms buffered by neurologic reserve. As brain loss from normal aging and MS continues, reserve is depleted and effects of subclinical MS disease activity and aging are unmasked, manifesting as PrMS. Most therapies show limited benefit in PrMS; patients are older, have fewer inflammatory events, and the effects of aging cause continued loss of neurologic function, even if inflammation is terminated. Loss of neurologic reserve means patients with PrMS cannot recover function, unlike patients with RMS.
Authors: Anna M Hedman; Neeltje E M van Haren; Hugo G Schnack; René S Kahn; Hilleke E Hulshoff Pol Journal: Hum Brain Mapp Date: 2011-09-13 Impact factor: 5.038
Authors: Anna He; Bernd Merkel; James William L Brown; Lana Zhovits Ryerson; Ilya Kister; Charles B Malpas; Sifat Sharmin; Dana Horakova; Eva Kubala Havrdova; Tim Spelman; Guillermo Izquierdo; Sara Eichau; Maria Trojano; Alessandra Lugaresi; Raymond Hupperts; Patrizia Sola; Diana Ferraro; Jan Lycke; Francois Grand'Maison; Alexandre Prat; Marc Girard; Pierre Duquette; Catherine Larochelle; Anders Svenningsson; Thor Petersen; Pierre Grammond; Franco Granella; Vincent Van Pesch; Roberto Bergamaschi; Christopher McGuigan; Alasdair Coles; Jan Hillert; Fredrik Piehl; Helmut Butzkueven; Tomas Kalincik Journal: Lancet Neurol Date: 2020-03-18 Impact factor: 44.182
Authors: Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: Christina J Azevedo; Steven Y Cen; Amir Jaberzadeh; Ling Zheng; Stephen L Hauser; Daniel Pelletier Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-09-25
Authors: Laura Bierhansl; Hans-Peter Hartung; Orhan Aktas; Tobias Ruck; Michael Roden; Sven G Meuth Journal: Nat Rev Drug Discov Date: 2022-06-06 Impact factor: 112.288
Authors: Massimo Filippi; Maria Pia Amato; Diego Centonze; Paolo Gallo; Claudio Gasperini; Matilde Inglese; Francesco Patti; Carlo Pozzilli; Paolo Preziosa; Maria Trojano Journal: J Neurol Date: 2022-05-24 Impact factor: 6.682